Uploads
Contact
/
Login
Upload
Search Results for 'Metastatic Nsclc'
Raising the Bar in the Management of Advanced/Metastatic NSCLC
debby-jeon
Antiangiogenic Agents in Advanced NSCLC
ellena-manuel
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
olivia-moreira
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
stefany-barnette
EGFR-Mutated Advanced NSCLC
sherrill-nordquist
The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature
stefany-barnette
James Yang,
pasty-toler
Thierry
cheryl-pisano
David R.
alida-meadow
Michael
luanne-stotts
Using Non-targeted Therapies in Targeted Lung Cancer Popula
ellena-manuel
MEK Inhibitors and their potential role in relapsed NSCLC
debby-jeon
Control #: 351
olivia-moreira
Niloofar
myesha-ticknor
Comparision
jane-oiler
The Role of Antiangiogenic Agents
luanne-stotts
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
pasty-toler
Please note, these are the actual video-recorded
min-jolicoeur
Translating NGS Data into a Clinically Actionable Assay
danika-pritchard
Secondaries
calandra-battersby
To date, several case reports have demonstrated response to therapy targeting the PD1
test
“Tumor cells
celsa-spraggs
NSCLC with high PD-L1 expression on tumor cells or tumor-in
test
update in metastatic breast c
min-jolicoeur
1
2
3
4
5
6